Jiaqin (Jack) Yao, Ph.D.
Topic
Nonclinical Safety Evaluation of PROTAC Products
Dr. Yao will discuss the following points:
- Targeted protein degradation (TPD)
- Proteolysis targeting chimera (PROTAC)
- Protein of interest (POI).
Speakers
Dr. Jiaqin Yao currently is the Chief Scientific Officer (CSO) of the Shanghai InnoStar Bio-Tech Co., Ltd. Dr. Yao received his medical training and master’s degree from the Shanghai Medical University (the current Fudan University Shanghai Medical College) and his Ph.D. in Toxicology from the University of Cincinnati. Following his post-doctoral training in the University of Illinois at Chicago, Dr. Yao joined the Center of Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) as a nonclinical reviewer in 2003. He had 16 years of FDA review experience with numerous IND, NDA, and BLA submissions. Dr. Yao was a member of the Genetic Toxicology Subcommittee in FDA/CDER and a member of three working groups, Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Endocrine Disruptor Working Group (EDWG), Immunotoxicity Working Group (IWG), and Pyrogenicity Working Group (PWG). Dr. Yao was also a Board member of the US Genetic Toxicology Association (GTA) and the American Association of Chinese for Toxicology (AACT, a Special Interest Group of the Society of Toxicology).
When
Dec 10 (Sat), 2022
7:00 – 9:00 pm
Where
Zoom meeting (online only)
Free Registration
click here
Questions
Email: Sabpa.ocla@gmail.com
